according to Read the full report: Based on the type of therapy, the allogeneic stem cell therapy segment is estimated to command the larger share of the global stem cell therapy market in 2016.
The report analyzes the stem cell therapy market by type, therapeutic application, cell source, and region- Product Development/Innovation: Detailed insights on research and development activities, developmental product pipeline, and new product launches in the stem cell therapy market- Market Development: Comprehensive information about the lucrative emerging markets.
The stem cell therapy market is niche industry with a growing number of global and local companies involved in the development and commercialization of stem cell therapy products.
The North American region is expected to command the largest share in the stem cell therapy market in 2016.
The stem cell therapy market report strategically profiles the key players who are involved in the manufacturing and commercialization of stem cell therapy products and comprehensively analyze their market ranking and core competencies.
As it stated in
Did Gene Therapy Cure Sickle Cell Disease?
The intention is to use this gene therapy to treat those with severe sickle cell disease and another condition called beta-thalessemia.
Gene Therapy in a Patient with Sickle Cell Disease.
Roughly 90,000 Americans have Sickle Cell Disease.
Sickle Cell Disease is an inherited condition that causes a mutated hemoglobin—the protein within red blood cells (RBCs) that carries oxygen for delivery to vital tissues.
Sickle Cell is a disease that is ripe for genetic advances for a few reasons.
As it stated in A French teen who was given gene therapy for sickle cell disease more than two years ago now has enough properly working red blood cells to dodge the effects of the disorder, researchers report.
“It shows gene therapy is on the right track.”
Full results have not been reported, but the gene therapy has not taken hold as well in some of them as it did in the French teen.
Gene therapy offers hope of a lasting one.
About 90,000 people in the U.S., mostly blacks, have sickle cell, the first disease for which a molecular cause was found.
This content may collect you by Victoria Hunter